Phase 1 SAD study of efprezimod alfa in healthy volunteers

Phase 1, randomised, double-blind trial of efprezimod alfa in graft-versus-host disease (GVHD) (2 arms), sponsored by Merck & Co. Primary endpoint: Assessment of Safety Based Primarily on the Frequency and Nature of Adverse Events, Clinical Laboratory Assessments, Physical Examinations, Vital Signs, 12-lead ECGs, and Telemetry Monitoring. Started Jun 2014; status: completed.